The 2019 AAD Annual Meeting was filled with broad innovations covering the entire field of dermatology. In this report, you will find several highlights.
Innovation in dermatology is no longer limited to a few areas. For example, innovations in psoriasis have expanded to atopic dermatitis, hidradenitis suppurativa, urticaria, and vitiligo. Important innovations are biologics with different targets but also small molecules, including Janus kinase inhibitors. In particular, several IL-17 and IL-23 blockers have opened new perspectives for long-term control of psoriasis. Anti-IL-4 and IL-13 are the new options for the treatment of atopic dermatitis.
Also covered in this conference report are new leads on hair loss, vitiligo, and non-melanoma skin cancers. The cl...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Secukinumab maintains improvements in psoriasis through 5 years of treatment Next Article
Certolizumab: Long-term safety and efficacy results for psoriasis-related nail disease in patients with moderate-to-severe plaque psoriasis »
Table of Contents: AAD 2019
Atopic Dermatitis: Many New Therapies in the Pipeline
Psoriasis and Biologics: The Beat Goes On
JAK Inhibitors: A New Frontier in Dermatology
Hair Loss: No Reason for Therapeutic Nihilism
Vitiligo: The Beginning of a New Era
What's New and Hot in Acne
Pearls of the Posters
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.